CellCentric

We’re excited to announce the initiation of DOMMINO-1, our pivotal Phase 2 trial of inobrodib + pom + dex (InoPd) in relapsed/refractory multiple myeloma. The first patient has been dosed, and enrollment is underway across the UK and US. Details: cellcentric.com/press-release/…

Majority of heavily pretreated relapsed/refractory #MM patients receive care in community settings. Inobrodib is our investigational oral drug + novel MoA. Delivered with pom/dex, we aim to address an unmet need for people who relapsed or weren’t eligible for TCE/BCMA agents.

We strive to maintain a workplace where we show up for one another & the people with cancer we aim to serve. On #EmployeeAppreciationDay, we celebrate our team. Together, we move toward our shared vision to improve the lives of those with cancer. Join us: cellcentric.com/careers

MM is a complex blood cancer that remains incurable for many. On #RareDiseaseDay, we recognize the individuals, families and communities impacted and the ongoing need for better, longer-lasting treatment options. We’re proud to be working to reshape care for rare cancers like MM.

CellCentric is headed to 📍Boston next week! We look forward to connecting with the investor community to share our progress advancing inobrodib, our first-in-class investigational oral therapy for the treatment of #multiplemyeloma.

Inobrodib is our investigational oral drug with a novel MoA. Delivered as a capsule, and used as part of an all-oral regimen with pom/dex (InoPd) for later line patients, it suits community-based care + may improve access for those with later stage #MM. Pivotal studies this year.

We have a deep appreciation for the women in STEM who drive innovation forward. On #IDWGS, we’re proud to recognize the women at CellCentric whose expertise, collaboration and commitment help advance science for people living with #multiplemyeloma. Learn more below. #WomeninSTEM

Every person’s experience with cancer is unique. That belief drives our people-centered approach: listening, understanding the needs of those impacted by #cancer and advancing innovation for communities with significant unmet need, including #MM. #WorldCancerDay #UnitedByUnique

CellCentric is headed to San Francisco for #JPM26! We look forward to connecting with the healthcare community and partners who share our vision for addressing unmet needs in #multiplemyeloma through novel, differentiated innovation. See you there!

As an all-oral regimen, InoPd has potential to enhance how #MM is managed in the community setting, where 70%+ of patients are treated. A well-tolerated and accessible treatment option, we believe InoPd could transform care for patients after, or instead of, BCMA/TCE agents.

New Phase 2 data at #ASH25 from our investigational, all-oral therapy InoPd (inobrodib + pom/dex) show promising clinical efficacy & tolerable safety profile in heavily pretreated patients with relapsed/refractory #MM. Initial positioning, after bispi. cellcentric.com/press-release/…

Many #MM patients either are ineligible for a bispecific or cannot tolerate the treatment within the first few months. More to come @ #ASH25 from our Phase 2 expansion arm data of InoPd, with potential to address a major unmet need in the post-BCMA/TCE therapy patient population.

Many patients have no other options after relapsing on or not tolerating BCMA/TCE therapies; this is a significant new unmet need in long-term #MM care. With a novel MoA & all-oral regimen, InoPd can help reduce burden, support equity & give patients control. More @ #ASH25.

Looking forward to connecting in London to discuss the science & strategy behind inobrodib, our first-in-class oral p300/CBP inhibitor for #MM. Our near-term aim: offer an option for patients who relapsed on or weren’t eligible for TCE/BCMA therapies-a major & growing unmet need.

People with #MM often become resistant to IMiDs, a widely-used class of treatments that includes pom. Our investigational medicine inobrodib, has a synergistic mechanism with IMiDs such as pom, helping to re-sensitize tumors & potentially restore treatment response. More @ #ASH25

We’re excited to share that we will be presenting a poster on our novel investigational medicine inobrodib for the treatment of #multiplemyeloma at #ASH25 in December. Read the full release: cellcentric.com/press-release/…

We’re #hiring! Join our team as a Senior Clinical Supplies Manager and help us transform outcomes for people living with #multiplemyeloma. This is an initial 9 month contract with potential for extension. Learn more and apply today by emailing careers@cellcentric.com.

70%+ #MM patients are treated in a community setting. Accessibility matters. Community-based care extends reach, reduces disruption & eases burden on the healthcare system. InoPd, our all-oral regimen, has a novel MoA. Pivotal studies next year. Learn more bit.ly/49nmx46

Bi-specifics have transformed #MM care.  Many patients ultimately relapse on these therapies, or cannot access, or are not eligible for them. InoPd, our all-oral regimen of inobrodib + pom+dex, is being developed to address this need & improve outcomes for people with MM.

Our all-oral InoPd (inobrodib + pom+dex) is moving into registration studies for relapsed/refractory #multiplemyeloma. It could improve community care with a truly novel mechanism and new treatment options. Learn more: cellcentric.com/inobrodib/